Navigation Links
When It Comes to Natural Remedies for Hormonal Balance, the Proof Is in the Clinical Research
Date:6/12/2009

Femmenessence: Proven to Regulate Hormone Levels in Women

SAN FRANCISCO, June 12 /PRNewswire/ -- Women approaching and exiting menopause are in a bind. As hormone levels fluctuate and decline, they experience a range of uncomfortable symptoms that can include hot flashes, night sweats, mood decline, and loss of libido. As common as these symptoms are, women's options for relief are limited. Researchers reported in 2002 that the hormone replacement therapy Prempro(R), which introduces foreign estrogens, obtained from pregnant mare's urine, into a woman's body, increased rates of breast cancer and stroke, (per JAMA 2002; 288:321-333.) causing American women to reject the drug en masse. While natural products that promise relief from menopausal symptoms abound, few have success rates higher than 50% and none have been clinically proven to regulate hormone levels; with one exception: Natural Health International's Femmenessence, made from the proprietary ingredient Maca-GO(R), www.naturalhi.com, a concentrated organically certified, proprietary formulation of the Peruvian herb maca.

Hormones are the body's directors, controlling the activity of cells and organs, affecting much more than just menopausal symptoms. "Hormones are profoundly important to a woman's health - hormones affect a woman's mood and cognitive function, they directly affect a woman's bone density, and hormones are without a doubt the most important factor of a woman's cardiovascular health," explains James Frame, CEO of Natural Health International (NHI), a vertically integrated San Francisco based health and dietary supplement company.

The subject of four published studies, the Femmenessence line includes two hormone-balancing products for women entering or leaving "the change of life": MacaLife(R) for peri-menopausal women experiencing hormonal fluctuations, and MacaPause(R) for post-menopausal women experiencing loss of hormone production. Peri-menopause is the 1-10 year period in which a woman's body transitions into menopause.

Femmenessence does not introduce any foreign hormones into the system. It simply supports the body's ability to balance (either increase or decrease) levels of its own hormones. Passing stringent pharmacology, toxicology and double blind placebo controlled clinical trials for health and safety, Femmenessence is as safe and side effect-free as your own hormones have been throughout your life.

However, the products are very different to other Maca based products and are not interchangeable, both due to the concentrated levels of the full spectrum of active constituents, and multiple phenotypes. "Something a lot of people don't realize is that there are 13 different phenotypes within Maca, and amazingly some of those phenotypes actually elicit different physiological effects," said Frame. NHI researched what the different phenotypes do and formulated Femmenessence MacaLife(R) and Femmenessence MacaPause(R) accordingly. MacaLife(R) is formulated for relief of menopausal symptoms, while MacaPause(R) is focused on supporting foundational health after menopause, such as heart health, bone health, mental health and hormonal balance.

About Natural Health International

Natural Health International was founded in 1997 as a raw material supply business in Sydney, Australia, that today has expanded internationally and merged with a leading research and development company. One of the few dietary supplement companies in the world that is vertically integrated, NHI grows its own herbs and maintains complete control over the manufacturing and distribution of its products. All NHI products are packaged in oxygen-barrier blister packs, recycled light-proof cardboard boxes, and are printed with vegetable ink. NHI products are available through selected health food stores such as Whole Foods, PCC, NRG and Pharmaca, as well as online at www.naturalhi.com.

For more information on NHI, the Femmenessence product line, or media related inquiries, contact Jennifer Bryan 805-962-1347 or at jbryan@christiecomm.com.


'/>"/>
SOURCE Natural Health International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
2. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
3. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
4. Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
5. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
6. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
7. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
8. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
9. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
10. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
11. Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Business Report" report to their offering. ... This report analyzes the worldwide markets for Dental Implants ... Canada , Japan , ... , and Rest of World. Annual estimates and ...
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets has announced ... 2016" report to their offering. ... The IPF pipeline is very strong with a total of ... Co., Inc., Biogen and Sanofi are involved in the development of the ... one is in Phase III stage, 15 are in Phase II stage, ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and ... 2015 through 2022. Also, a six-year historic analysis is provided for these ...
Breaking Medicine Technology:
(Date:3/24/2017)... , ... March 24, 2017 , ... ... of inspiring stories about real people of God in congregations across the United ... Miller, a Presbyterian minister ordained in 1964 who has served congregations in seven ...
(Date:3/23/2017)... Greensboro, NC & Seattle, WA (PRWEB) , ... March 23, 2017 ... ... international public health emergency and now estimates that there could be four million Zika-related ... fastest growing epidemics to date with numbers of US cases reported per year skyrocketing ...
(Date:3/23/2017)... Houston, Texas (PRWEB) , ... March 23, 2017 , ... ... their 3rd location in the greater Houston Area. The new location is located at ... St. Luke’s Hospital in Springwoods Village. This newest location will provide patients living in ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... Gruene Road in Building 2. The clinic is the group’s second in New Braunfels ... opening the company’s second New Braunfels location brings things full circle for the group, ...
(Date:3/23/2017)... ... 23, 2017 , ... The IoT (Internet of Things) is revolutionizing the way ... impact on businesses and individual consumers alike. Laboratories can maximize their profit margin ... anywhere from $4 trillion to $11 trillion dollars by the year 2025. McKinsey expects ...
Breaking Medicine News(10 mins):